Retinal Vascular Occlusion is an indication for drug development with over 40 pipeline drugs currently active. According to GlobalData, preregistered drugs for Retinal Vascular Occlusion have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Retinal Vascular Occlusion compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Retinal Vascular Occlusion overview
Retinal vascular occlusion is a condition that affects the blood vessels in the retina, the light-sensitive layer of tissue at the back of the eye. It occurs when a blood vessel is blocked by a clot or compressed by another vessel, preventing blood from reaching or leaving the retina. This can cause vision loss or blindness in the affected eye. There are two main types of retinal vascular occlusion: retinal artery occlusion and retinal vein occlusion. Both types can have serious complications, such as swelling, bleeding, or abnormal blood vessel growth in the eye. Retinal vascular occlusion is more common in middle-aged and older people, and in people with risk factors such as atherosclerosis, high blood pressure, diabetes, or blood clotting disorders. The diagnosis is based on a comprehensive eye exam and tests such as a fundus photography, fluorescein angiography, or optical coherence tomography. The treatment depends on the type and severity of the occlusion, and may include medication injections, laser therapy, or surgery. The goal of treatment is to prevent or reduce vision loss and complications.
For a complete picture of PTSR and LoA scores for drugs in Retinal Vascular Occlusion, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
